Substituted imidazoquinolines and imidazonaphthyridines

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4745 (2006.01)

Patent

CA 2597446

Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

L'invention concerne des imidazoquinolines et des imidazonaphthyridines comprenant un substituant qui contient un groupe fonctionnel, par exemple, un groupe amide, sulfonamide, urée ou hétérocyclyle, à la position 6, 7, 8 ou 9. L'invention concerne également des compositions pharmaceutiques contenant lesdits composés, des intermédiaires, des procédés de production et des procédés d'utilisation de ces composés comme immunomodulateurs, afin d'activer la biosynthèse des cytokines chez les animaux et de traiter des maladies, notamment, des maladies virales et néoplasiques.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Substituted imidazoquinolines and imidazonaphthyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted imidazoquinolines and imidazonaphthyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted imidazoquinolines and imidazonaphthyridines will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1355087

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.